"In order to meet the rapidly growing demand of generics, the Kyowa board has proposed the setting-up of a two billion tablets capacity plant at Tottori, Japan which would be designed to efficiently handle mass volume products and provide flexibility in allowing easy future expansion," Lupin Ltd said in a regulatory filing.
Kyowa Pharmaceutical Industry Co is a wholly-owned subsidiary of the the Mumbai-based firm. It has a manufacturing facility at Sanda, Japan.
Lupin shares roday settled at Rs 1,752.15 on BSE, up 1.42 per cent from the previous close.